Myxofibrosarcoma (MFS): Why It Comes Back & How It's Treated

What Is Myxofibrosarcoma?

Myxofibrosarcoma (MFS) is a type of soft tissue sarcoma — a cancer that arises from the connective tissues of the body rather than from an organ lining. It develops from fibroblast-like cells in the soft tissues and is one of the commonest soft tissue sarcomas in people over the age of 50. The name itself describes what the pathologist sees down the microscope: "myxo" for the gel-like, mucin-rich (myxoid) background the tumour cells sit in, and "fibrosarcoma" for the spindle-shaped, fibre-producing cancer cells. You may also see it written under its older label, myxoid malignant fibrous histiocytoma (myxoid MFH) — modern pathology has reclassified that term, but it refers to the same disease.

MFS most often appears in the arms, legs, shoulders and hips — and unlike many deep sarcomas, a large share of cases sit in the subcutis, the fatty layer just beneath the skin. People sometimes search for myxofibrosarcoma skin involvement for exactly this reason: a slow-growing lump close to the surface can look deceptively harmless. It is closely related to, and shares features with, undifferentiated pleomorphic sarcoma (UPS / MFH), and high-grade MFS can be difficult to tell apart from UPS without expert pathology. For the full clinical picture across all subtypes, see our sarcoma — overview hub.

What Does It Feel Like? Symptoms to Know

The typical presentation of MFS is a painless, slowly enlarging lump — often present for months before someone seeks help precisely because it does not hurt. Because it favours the layer just under the skin, the lump may feel firm and be visible or easily felt, rather than buried deep in muscle. Warning signs that any soft tissue lump deserves urgent specialist assessment include a lump that is larger than about 5 cm, one that is growing, one that sits deep to the fascia, or — particularly relevant to MFS — a lump that has grown back after a previous removal. MFS is one of the sarcomas most likely to recur at the site of earlier surgery, so a "lump that came back" should always be biopsied, never simply removed again.

Why Myxofibrosarcoma Has a Reputation for Coming Back

Among all the soft tissue sarcomas, myxofibrosarcoma is one of the most likely to recur in the same place after surgery. This is not bad luck — it is biology. MFS does not grow as a neat, rounded ball with a clean boundary. Instead, its edge sends out microscopic, finger-like projections that infiltrate along the planes of fascia and through the fatty tissue around it. On imaging and at operation this shows up as a "tail" trailing away from the main mass — and crucially, the cancer cells extend even further than that tail, into tissue that looks and feels completely normal.

The practical consequence is simple but important: if a surgeon removes only the lump they can see and feel, they will almost certainly leave MFS cells behind. Those residual cells regrow, and the recurrence is often higher-grade and harder to treat than the original tumour. This is why myxofibrosarcoma demands wide margins planned around the tail, careful pathology of every edge, and frequently radiation to mop up the microscopic disease that surgery cannot guarantee to clear. It is also why MFS should never be treated as "just a cyst" or "just a lipoma" and shelled out in a minor procedure.

How Myxofibrosarcoma Is Graded — Low, Intermediate and High

Once the biopsy confirms MFS, the pathologist assigns a grade, which describes how aggressive the tumour looks and predicts how it is likely to behave. Grading is usually done with the FNCLCC system, which scores how abnormal the cells appear (differentiation), how fast they are dividing (mitotic count), and how much dead tissue is present (necrosis). Those scores combine into a grade. Grade matters more for prognosis and for the risk of spread than almost anything else — but, importantly, it does not change the fact that every grade of MFS needs wide surgery, because even low-grade tumours carry the same infiltrative, recurrence-prone edge.

A practical point that surprises many patients: a tumour can change grade over time, and a recurrence is often higher-grade than the original. A low-grade MFS removed without adequate margins can come back as an intermediate- or high-grade tumour years later. This is the strongest possible argument for getting the very first operation right — and for having your slides reviewed by a pathologist who sees sarcomas regularly, because distinguishing low-grade MFS from a benign myxoid lesion, or high-grade MFS from undifferentiated pleomorphic sarcoma (UPS / MFH), takes real expertise.

How CION Diagnoses and Treats Myxofibrosarcoma

The single biggest mistake made with myxofibrosarcoma is operating on the lump before anyone knows what it is. At CION, every suspicious soft tissue mass is worked up in a fixed order so the surgery is planned around the tumour's true extent, not just the palpable lump.

Step 1 — MRI Maps the Tumour and Its Tail

MRI is the imaging investigation of choice for any soft tissue sarcoma, and it is especially valuable in MFS because it can reveal the characteristic infiltrative tail trailing along the fascia. The scan shows the tumour's size, its depth relative to the fascia, and its relationship to nearby muscles, nerves and blood vessels — the information the surgeon needs to draw a margin that captures the tail, not just the lump.

Step 2 — Image-Guided Core Needle Biopsy

A core needle biopsy confirms that the mass is MFS and assigns its grade. CION plans the biopsy in coordination with the operating surgeon, so the needle enters along a track that can later be excised in one piece with the tumour. A biopsy placed carelessly contaminates clean tissue and can force a far larger operation — so in sarcoma, biopsy planning is part of surgical planning.

Step 3 — Staging With a Chest CT

Because higher-grade MFS can spread to the lungs, a chest CT is performed to check for metastases before treatment is finalised. This determines whether the plan is purely local (surgery and radiation) or whether systemic treatment is also needed.

Step 4 — Wide Local Excision With Tail-Aware Margins

The mainstay of cure is wide local excision: removing the tumour together with a generous cuff of normal tissue and the infiltrative tail in one block, aiming for a margin-negative (R0) result. For limb tumours this is performed as limb-sparing surgery wherever possible. Because the microscopic edge of MFS extends beyond what is visible, the surgeon plans the margin deliberately wider than for many other sarcomas — and the specimen is orientated so the pathologist can report exactly which edge, if any, is involved.

Step 5 — Radiation, and Chemotherapy When Needed

Radiation — given before surgery (neoadjuvant) to sterilise the tumour's edge, or after surgery (adjuvant) to treat the surgical bed — is used frequently in MFS to control the high local recurrence risk, especially for intermediate- and high-grade tumours or when the margin is close. Chemotherapy is considered for high-grade disease or where the cancer has spread. Every one of these decisions is made together at CION's multidisciplinary tumour board, not by any single doctor in isolation.

Prognosis, Follow-Up and Cost in Hyderabad

The outlook for myxofibrosarcoma depends most on its grade and on whether the first surgery achieved a clear, tail-inclusive margin. Low-grade MFS that is widely excised has an excellent outlook for survival, though it still needs long-term watching because of its tendency to recur locally. High-grade MFS carries a higher risk of spread to the lungs and is treated more intensively. The most important modifiable factor is the quality of that first operation — which is why specialist, planned surgery makes such a difference to long-term results.

Because MFS recurs locally more often than most sarcomas, follow-up is structured and long: regular clinical examination and surveillance MRI of the operated area to catch a local recurrence early, alongside periodic chest imaging to monitor for lung spread in higher-grade tumours. Catching a recurrence while it is small keeps a further limb-sparing operation possible.

Indicative Cost in Hyderabad

Costs are indicative. A personalised estimate is provided after your CION consultation. EMI options and cashless support through major TPAs, Aarogyasri, CGHS, ECHS & ESI are available for eligible patients.

Why Patients Choose CION for Myxofibrosarcoma

MFS is unforgiving of a narrow first operation. Here is why patients trust CION to plan the surgery around the whole tumour — tail and all.

Don't Let Myxofibrosarcoma Get a Second Chance

A planned, tail-aware wide excision by a sarcoma specialist gives you the best chance of clearing MFS the first time — and the lowest chance of it coming back. If you have an MFS diagnosis or a worrying report, talk to us first.